Enteric Neurons In Parkinson'S Disease is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.
The enteric nervous system (ENS) contains millions of neurons distributed throughout the gastrointestinal tract and serves as the "second brain." Parkinson's disease (PD) frequently involves the ENS, with gastrointestinal dysfunction (constipation, nausea, bloating) often predating motor symptoms by years. Lewy pathology in enteric neurons is a hallmark of PD progression.
The ENS is organized into two major ganglionated plexuses:
Myenteric Plexus (Auerbach's Plexus):
- Located between circular and longitudinal muscle layers
- Primary regulator of gut motility
- Coordinates peristalsis
Submucosal Plexus (Meissner's Plexus):
- Located in the submucosa
- Regulates intestinal secretion
- Controls mucosal blood flow
- Primary Afferent Neurons: Sense gut wall distension and luminal contents
- Motor Neurons: Control smooth muscle (excitatory/inhibitory)
- Interneurons: Coordinate reflex circuits
- Secretomotor Neurons: Regulate secretion and blood flow
- Cholinergic: Excitatory motor neurons, secretomotor
- Nitrergic (NOS): Inhibitory motor neurons
- VIPergic: Secretomotor, vasodilatory
- 5-HT: Enteric serotonin neurons
-
Motility Control:
- Peristaltic reflexes
- Segmentation
- Migrating motor complexes
-
Secretion Regulation:
- Fluid and electrolyte balance
- Mucosal protection
- Hormone release
-
Immune Modulation:
- Gut-brain axis signaling
- Microenvironment control
The ENS communicates with the CNS through:
- Vagal Afferents: 80% of vagus nerve fibers are sensory
- Spinal Afferents: Dorsal root ganglia
- Neuroimmune Signaling: Cytokine-mediated
- Microbiome-Derived Signals: Microbial metabolites
Pre-motor Phase:
- Constipation (most common)
- Delayed gastric emptying
- Small intestinal bacterial overgrowth (SIBO)
Motor Phase:
- Worsening constipation
- Fecal incontinence
- Dysphagia
Distribution:
- Esophagus → Stomach → Intestines → Colon
- Proximal gut affected before distal
- Myenteric plexus prominently involved
Mechanisms:
- α-Synuclein aggregation
- Lewy body formation
- Neuronal dysfunction and death
The dual-hit hypothesis proposes:
- Pathogen enters via olfactory or GI route
- α-Synuclein spreads retrogradely via vagus nerve
- Brainstem involvement precedes substantia nigra
- Increased intestinal permeability ("leaky gut")
- Elevated pro-inflammatory cytokines
- Microglia activation
- Altered microbiome composition
-
GI Symptom Treatment:
- Laxatives (fiber, osmotic, stimulant)
- Prokinetics (metoclopramide)
- Botulinum toxin for achalasia
-
Dietary Interventions:
- High-fiber diet
- Adequate hydration
- Probiotics
-
Disease-Modifying:
- Anti-α-synuclein antibodies
- Neuroprotective agents
- Anti-inflammatory treatments
-
Microbiome Modulation:
- Fecal microbiota transplantation (FMT)
- Prebiotics and probiotics
- Dietary interventions
-
Gut-Brain Axis:
- Vagal nerve stimulation
- ENS electrical stimulation
- Growth factor delivery
- α-Synuclein Overexpression: Transgenic mice
- 6-OHDA Lesions: Vagal afferent degeneration
- MPTP Model: GI dysfunction component
- Germ-Free Animals: Microbiome studies
- Autopsy Studies: Lewy bodies in ENS
- Colonic Biopsies: α-Synuclein detection
- Capsule Endoscopy: Small bowel assessment
- α-Synuclein in GI: Rectal/colon biopsies
- Intestinal Permeability: Lactulose/mannitol test
- Microbiome Analysis: 16S rRNA sequencing
- Inflammatory Markers: CRP, IL-6, TNF-α
The study of Enteric Neurons In Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Braak H, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211.
- Sampson TR, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell. 2016;167(6):1469-1480.
- Travagli RA, et al. Brainstem NOS and the vagal control of gastric motility. Neurogastroenterol Motil. 2020;32(1):e13784.
- Clairembault T, et al. Enteric alpha-synuclein as a trigger for Parkinson's disease: Mechanisms and therapeutic strategies. Neuropharmacology. 2020;168:107785.
- Mulak A, Bonaz B. Brain-gut-microbiota axis in Parkinson's disease: A bidirectional pathway. World J Gastroenterol. 2015;21(46):12987-13001.
- Cersosimo MG, Benarroch EE. Neural control of the gastrointestinal tract: Implications for Parkinson disease. Nat Rev Gastroenterol Hepatol. 2021;18(10):641-656.
- Scheperjans F, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord. 2015;30(3):350-358.
- Klingelhoefer L, Reichmann H. Pathogenesis of Parkinson disease - The gut-brain axis and environmental factors. Nat Rev Neurol. 2015;11(11):625-636.